易明医药(002826) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥171,430,742.25, a decrease of 8.05% compared to ¥186,434,809.99 in the same period last year[4] - Net profit attributable to shareholders was ¥8,363,504.12, down 1.93% from ¥8,528,415.37 year-on-year[4] - Total operating revenue for Q1 2023 was CNY 171,430,742.25, a decrease of 8.5% compared to CNY 186,434,809.99 in Q1 2022[28] - Net profit for Q1 2023 was CNY 8,478,872.65, slightly down by 1.9% from CNY 8,639,617.30 in Q1 2022[30] - The total comprehensive income for Q1 2023 was CNY 8,391,700.71, compared to CNY 8,637,294.56 in Q1 2022, indicating a decrease of 2.8%[30] Cash Flow - The net cash flow from operating activities increased significantly to ¥31,828,337.43, a 713.24% improvement from -¥5,190,203.15 in Q1 2022[10] - Cash inflow from operating activities increased to CNY 224,475,914.77 in Q1 2023, compared to CNY 211,295,382.30 in Q1 2022, reflecting a growth of 6.2%[32] - The net cash flow from investing activities was -¥100,219,757.00, which is a decline of ¥51,446,057.00 year-over-year[34] - The net cash flow from financing activities was -¥462,499.99, indicating no cash inflow from financing activities[34] - The net increase in cash and cash equivalents was -¥68,936,595.76, compared to a decrease of ¥56,638,556.05 in the previous period[35] - The ending balance of cash and cash equivalents was ¥207,346,181.35, down from ¥276,282,777.11 at the beginning of the period[35] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,015,182,951.21, a slight decrease of 0.30% from ¥1,018,204,645.88 at the end of the previous year[5] - The company's total liabilities decreased to CNY 256,795,042.24 in Q1 2023 from CNY 268,208,437.62 in Q1 2022, a reduction of 4.3%[26] - The total current assets as of March 31, 2023, amount to ¥578,091,376.85, slightly up from ¥575,009,326.03 at the beginning of the year[23] - The total assets of the company are ¥1,015,182,951.21, down from ¥1,018,204,645.88 at the beginning of the year[24] - The accounts receivable decreased from ¥162,609,114.23 to ¥129,932,347.05 during the reporting period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,848[12] - The largest shareholder, Gao Fan, holds 25.59% of shares, amounting to 48,800,382 shares, with 17,120,000 shares pledged[12] Investments and Expenses - Research and development expenses decreased by 51.49% to ¥498,451.91 from ¥1,027,543.70 in the same period last year[9] - The company reported a significant increase in credit impairment losses, which rose by 334.06% to ¥1,755,052.14 compared to a decrease of ¥749,839.71 in Q1 2022[9] - The company received government subsidies amounting to ¥582,278.88, which are closely related to its normal business operations[6] - The company has increased its short-term financial investments, with trading financial assets reaching ¥100,000,000.00, marking a 100% increase[9] - The company plans to invest $6,000,000 to acquire a 21.43% stake in Pier 88 Health Limited through its wholly-owned subsidiary TAPI Healthcare Inc.[15] Audit Information - The company did not undergo an audit for the first quarter report[36]